These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11206459)

  • 1. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.
    Johansson A; Hubatsch I; Akerblom E; Lindeberg G; Winiwarter S; Danielson UH; Hallberg A
    Bioorg Med Chem Lett; 2001 Jan; 11(2):203-6. PubMed ID: 11206459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3.
    Fischmann TO; Weber PC
    Curr Pharm Des; 2002; 8(28):2533-40. PubMed ID: 12369938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
    Dimasi N; Martin F; Volpari C; Brunetti M; Biasiol G; Altamura S; Cortese R; De Francesco R; Steinkühler C; Sollazzo M
    J Virol; 1997 Oct; 71(10):7461-9. PubMed ID: 9311825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase).
    Johansson A; Poliakov A; Akerblom E; Lindeberg G; Winiwarter S; Samuelsson B; Danielson UH; Hallberg A
    Bioorg Med Chem; 2002 Dec; 10(12):3915-22. PubMed ID: 12413843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.
    Llinàs-Brunet M; Bailey M; Déziel R; Fazal G; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2719-24. PubMed ID: 9873610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of selective eglin inhibitors of HCV NS3 proteinase.
    Martin F; Dimasi N; Volpari C; Perrera C; Di Marco S; Brunetti M; Steinkühler C; De Francesco R; Sollazzo M
    Biochemistry; 1998 Aug; 37(33):11459-68. PubMed ID: 9708981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease.
    Sperandio D; Gangloff AR; Litvak J; Goldsmith R; Hataye JM; Wang VR; Shelton EJ; Elrod K; Janc JW; Clark JM; Rice K; Weinheimer S; Yeung KS; Meanwell NA; Hernandez D; Staab AJ; Venables BL; Spencer JR
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3129-33. PubMed ID: 12372517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.
    Colarusso S; Gerlach B; Koch U; Muraglia E; Conte I; Stansfield I; Matassa VG; Narjes F
    Bioorg Med Chem Lett; 2002 Feb; 12(4):705-8. PubMed ID: 11844706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease.
    Ingallinella P; Bianchi E; Ingenito R; Koch U; Steinkühler C; Altamura S; Pessi A
    Biochemistry; 2000 Oct; 39(42):12898-906. PubMed ID: 11041854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
    Ingallinella P; Fattori D; Altamura S; Steinkühler C; Koch U; Cicero D; Bazzo R; Cortese R; Bianchi E; Pessi A
    Biochemistry; 2002 Apr; 41(17):5483-92. PubMed ID: 11969409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
    Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
    Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.
    Liu D; Wang YS; Gesell JJ; Wyss DF
    J Mol Biol; 2001 Nov; 314(3):543-61. PubMed ID: 11846566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals.
    Johansson A; Poliakov A; Akerblom E; Wiklund K; Lindeberg G; Winiwarter S; Danielson UH; Samuelsson B; Hallberg A
    Bioorg Med Chem; 2003 Jun; 11(12):2551-68. PubMed ID: 12757723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S; Wu W; Shih NY; George Njoroge F
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus NS3/4A protease.
    Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
    Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): model compounds towards small molecule inhibitors.
    Oscarsson K; Poliakov A; Oscarson S; Danielson UH; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Jul; 11(13):2955-63. PubMed ID: 12788365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.